CeNeS ready for US M6G studies
Cambridge, UK-based biopharmaceutical company CeNeS Pharmaceuticals says it has completed preparations for US trials of its developmental agent M6G (morphine-6-glucuronide). Specifically, the firm said that it has completed Phase I pharmacokinetic studies, which demonstrated that the drug has favorable linear kinetics with minimal accumulation.
Commenting on the preparations, CeNeS chief executive Neil Clark, said: "we are active in the partnering process and continue to have discussions with potential partners to collaborate and fund this program through to product launch."
In a related announcement, CeNeS said that it knows of no reason for the recent decline in the company's share price. The firm added that it has sufficient working capital and continues to make good progress in all of its operations.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze